sEH/FLAP-IN-2
sEH/FLAP-IN-2 is a selective sEH (IC50 = 12.6 nM)/FLAP dual inhibitor. sEH/FLAP-IN-2 highlights the reduction of 5-LOX/FLAP- and sEH-derived LMs, resulting in a favourable redistribution of LMs. sEH/FLAP-IN-2 can be used for the study of peritonitis.
For research use only. We do not sell to patients.
- Formula: C26H33N5O2
- Molecular Weight:447.57
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
sEH/FLAP-IN-2 (Compound 6) shows no significant inhibitory activity against 5-LOX, with an IC50 value >10 μM[1].
sEH/FLAP-IN-2 (10 μM, 15 min) significantly inhibits the formation of 5-LOX products (LTB4, trans-LTB4, and 5-HETE) in the FLAP-dependent system without exogenous arachidonic acid (AA) in human neutrophils, with a residual activity of 35.7%; in the presence of exogenous AA, its inhibitory activity was weakened (IC50 > 10 μM)[1].
sEH/FLAP-IN-2 (0.1-10 μM, 16 min) has no significant effect on the activities of COX-1, COX-2, and mPGES-1[1].
sEH/FLAP-IN-2 (0.1-10 μM, 120 min) concentration-dependently inhibits 5-LOX/FLAP-derived mediators (such as LTB4 and LTC4), especially in M1-MDM; simultaneously, it increases COX-derived prostaglandins (such as PGE2 and PGD2) but does not affect SPM (such as RvD5) levels[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CD-1 mice (33-39 g, 8 weeks old) were given an acute inflammatory response via intraperitoneal injection of Zymosan (HY-159069) (1 mg/mouse)[1].
-
Dosage:10 mg/kg
-
Administration:I.p., once, 30 mins before zymosan
-
Result:Significantly reduced zymosan-induced levels of pro-inflammatory mediators, including LTB4, 5-HETE, and LTE4.
Increased levels of anti-inflammatory EETs (particularly 11,12-EET and 14,15-EET) while decreasing levels of pro-inflammatory DHETs (such as 11,12-DHET), resulting in an elevated EET/DHET ratio.
PGE2 levels were significantly reduced, but TXB2 was unaffected.
Chemical Information
-
Molecular Weight 447.57
-
Formula C26H33N5O2
-
SMILES
O=C(NCC1=CC=C(N)C=C1)C2=CC=C(NC(NCC34CC5CC(C4)CC(C5)C3)=O)C=C2N
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Ciaglia T, et al. An adamantylureido-benzylamide aniline as FLAP/sEH dual inhibitor: Rational design, in vitro and in vivo lipidomic profiling. Eur J Med Chem. 2026 Jan 15;302(Pt 2):118338. [Content Brief]
[2]. Yang DM, et al. Discovery of novel indoline derivatives as potent small molecule PD-L1 inhibitors. Bioorg Med Chem Lett. 2026 Feb 1;131:130458. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
sEH/FLAP-IN-2 Related Classifications
HY-179441 Related Classifications
Powered by Bioz